ERAS compared with MAZE: revenue, margins and what each company keeps, and the suppliers and customers both name

ERASErasca, Inc.

Mkt capRevenueRevenue

MAZEMaze Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ERAS 5

—Emerge Life Sciences, Pteunlistedsupplier

—Guangzhou Joyo Pharmatechunlistedsupplier

—Medshine Discoveryunlistedsupplier

—Novartis Pharmaunlistedsupplier

1 more · ERAS chain ›

Shared 0

No shared counterparties.

Only MAZE 4

NBIXNeurocrine Biosciencescustomer

—Shionogiunlistedcustomer

—Trace Neuroscienceunlistedcustomer

—

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Alloy Therapeutics

unlistedcustomer

ERASErasca, Inc.

14.03▼−2.23%· post 14.03

Mkt cap$4.9BRevenue—

MAZEMaze Therapeutics, Inc.

30.37▼−3.53%· post 30.37

ClosedNov 2 '26

Mkt cap$1.8BRevenue$20MQ1 FY26

Compare

ClosedNov 2 '26

ERASErasca, Inc.

MAZEMaze Therapeutics, Inc.

14.03▼−2.23%post 14.03

Price

30.37▼−3.53%post 30.37

$4.9B

Mkt cap

$1.8B

—

Revenue

$20MQ1 FY26

ERAS14.03▼−2.23%vsMAZE30.37▼−3.53%ClosedNov 2 '26